Viking Therapeutics, Inc. (VKTX) Q2 2017 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 1.59%

Viking Therapeutics reported a loss per share of $0.21, which did not meet expectations, although no revenue figures were disclosed. The stock reacted negatively, dropping 1.59%. Investors may be concerned about the lack of guidance and clarity on financial performance moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.21	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management's commentary was neutral, emphasizing the importance of their clinical programs. No specific guidance was offered for future performance.

Management did not provide specific updates on revenue or future earnings expectations.

The focus remains on ongoing clinical trials and product development.

Viking Therapeutics Misses on EPS, Stock Down 1.59%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 1.59%

Key numbers

Management commentary